Antiviral treatment of influenza in South Korea

References

• Vaccines against influenza WHO position paper - November 2012. Wkly Epidemiol Rec 2012;87:461-76
   PubMedGoogle Scholar
• Nair H, Brooks WA, Katz M, et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet 2011;378:1917-30
   PubMed Web of Science ®Google Scholar
• Mertz D, Kim TH, Johnstone J, et al. Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis. BMJ 2013;347:f5061
   PubMed Web of Science ®Google Scholar
• Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012;12:36-44
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Talbot HK, Ohmit SE, et al. Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains. Clin Infect Dis 2012;55:951-9
   PubMed Web of Science ®Google Scholar
• Jefferson T, Jones M, Doshi P, et al. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 2014;348:g2545
   PubMed Web of Science ®Google Scholar
• Heneghan CJ, Onakpoya I, Thompson M, et al. Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 2014;348:g2547
   PubMedGoogle Scholar
• Santesso N, Hsu J, Mustafa R, et al. Antivirals for influenza: a summary of a systematic review and meta-analysis of observational studies. Influenza Other Respir Viruses 2013;7(Suppl 2):76-81
   PubMedGoogle Scholar
• Burch J, Paulden M, Conti S, et al. Antiviral drugs for the treatment of influenza: a systematic review and economic evaluation. Health Technol Assess 2009;13:1-265; iii-iv
   PubMed Web of Science ®Google Scholar
• Gani R, Hughes H, Fleming D, et al. Potential impact of antiviral drug use during influenza pandemic. Emerg Infect Dis 2005;11:1355-62
   PubMed Web of Science ®Google Scholar
• Jefferson T, Deeks JJ, Demicheli V, et al. Amantadine and rimantadine for preventing and treating influenza A in adults. Cochrane Database Syst Rev 2004:Cd001169
   Google Scholar
• Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet 2000;355:827-35
   PubMed Web of Science ®Google Scholar
• Spanakis N, Pitiriga V, Gennimata V, et al. A review of neuraminidase inhibitor susceptibility in influenza strains. Expert Rev Anti Infect Ther 2014;12:1325-36
   PubMed Web of Science ®Google Scholar
• Birnkrant D, Cox E. The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza. N Engl J Med 2009;361:2204-7
   PubMed Web of Science ®Google Scholar
• McNicholl IR, McNicholl JJ. Neuraminidase inhibitors: zanamivir and oseltamivir. Ann Pharmacother 2001;35:57-70
   PubMed Web of Science ®Google Scholar
• Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza – recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011;60:1-24
   PubMedGoogle Scholar
• Williams S, Fitzner J, Merianos A, et al. The challenges of global case reporting during pandemic A(H1N1). 2009;Bull World Health Organ 2014;92:60-7
   Google Scholar
• Meerhoff TJ, Simaku A, Ulqinaku D, et al. Surveillance for severe acute respiratory infections (SARI) in hospitals in the WHO European region - an exploratory analysis of risk factors for a severe outcome in influenza-positive SARI cases. BMC Infect Dis 2015;15:1
   PubMed Web of Science ®Google Scholar
• Radin JM, Hawksworth AW, Kammerer PE, et al. Epidemiology of pathogen-specific respiratory infections among three US populations. PLoS One 2014;9:e114871
   Web of Science ®Google Scholar
• Suh M, Kang DR, Lee DH, et al. Socioeconomic burden of influenza in the Republic of Korea, 2007-2010. PLoS One 2013;8:e84121
   PubMed Web of Science ®Google Scholar
• Wie SH, So BH, Song JY, et al. A comparison of the clinical and epidemiological characteristics of adult patients with laboratory-confirmed influenza A or B during the 2011-2012 influenza season in Korea: a multi-center study. PLoS One 2013;8:e62685
   PubMed Web of Science ®Google Scholar
• Lee JS, Shin KC, Na BK, et al. Influenza surveillance in Korea: establishment and first results of an epidemiological and virological surveillance scheme. Epidemiol Infect 2007;135:1117-23
   PubMed Web of Science ®Google Scholar
• Korea Centers for Disease Control and Prevention. Korea Influenza Surveillance Report, 2007-2008. Pub Health Wkly Rep 2008;1:377-83
   Google Scholar
• Western Pacific Region Global Influenza Surveillance and Response System. Epidemiological and virological characteristics of influenza in the Western Pacific Region of the World Health Organization, 2006-2010. PLoS One 2012;7:e37568
   Web of Science ®Google Scholar
• Hurt AC, Ho HT, Barr I. Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors. Expert Rev Anti Infect Ther 2006;4:795-805
   PubMedGoogle Scholar
• Colman PM. Zanamivir: an influenza virus neuraminidase inhibitor. Expert Rev Anti Infect Ther 2005;3:191-9
   PubMedGoogle Scholar
• Korea Centers for Disease Control and Prevention. Surveillance for antiviral drugs of influenza viruses isolated in Korea during 2007-2008 season. Pub Health Wkly Rep 2008;1:384-7
   Google Scholar
• Korea Centers for Disease Control and Prevention. Antiviral resistant influenza A viruses isolated in Korea during 2008-2009 season - Oseltamivir resistant to A/H1N1 in Korea. Pub Health Wkly Rep 2009;2:25-6
   Google Scholar
• Korea Centers for Disease Control and Prevention. Antiviral drug resistance of pandemic influenza A(H1N1) in Korea since 2009. Pub Health Wkly Rep 2011;3:332-3
   Google Scholar
• Lee JY. Antiviral drug resistance of influenza viruses isolated in Korea during 2010-2011 season. Pub Health Wkly Rep 2012;4:896-9
   Google Scholar
• Choi JH, Kim SJ, Kim NH. Antiviral drug resistance of influenza viruses isolated in Korea during 2011-2012 season. Pub Health Wkly Rep 2012;5:793-7
   Google Scholar
• Kim KA, Lee JY, Kim W, et al. Amantadine and zanamivir resistance of influenza A/H3N2 viruses isolated in Korea, 2002/03∼2003/04. J Bacteriol Virol 2008;38:127-37
   Google Scholar
• Choi WY, Kim S, Lee N, et al. Amantadine-resistant influenza A viruses isolated in South Korea from 2003 to 2009. Antiviral Res 2009;84:99-202
   Web of Science ®Google Scholar
• Cho HG, Choi JH, Kim WH, et al. High prevalence of amantadine-resistant influenza A virus isolated in Gyeonggi Province, South Korea, during 2005-2010. Arch Virol 2013;158:241-5
   PubMed Web of Science ®Google Scholar
• Lee J, Song YJ, Park JH, et al. Emergence of amantadine-resistant H3N2 avian influenza A virus in South Korea. J Clin Microbiol 2008;46:3788-90
   PubMed Web of Science ®Google Scholar
• Hauge SH, Dudman S, Borgen K, et al. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08. Emerg Infect Dis 2009;15:155-62
   PubMed Web of Science ®Google Scholar
• Choi WY, Yang I, Kim S, et al. The emergence of oseltamivir-resistant seasonal influenza A (H1N1) virus in Korea during the 2008-2009 season. Osong Public Health Res Perspect 2011;2:178-85
   PubMedGoogle Scholar
• Kim SG, Hwang YH, Shin YH, et al. Occurrence and characterization of oseltamivir-resistant influenza virus in children between 2007-2008 and 2008-2009 seasons. Korean J Pediatr 2013;56:165-75
   PubMedGoogle Scholar
• Yi H, Lee JY, Hong EH, et al. Oseltamivir-resistant pandemic (H1N1) 2009 virus, South Korea. Emerg Infect Dis 2010;16:1938-42
   PubMed Web of Science ®Google Scholar
• Shin SY, Kang C, Gwack J, et al. Drug-resistant pandemic (H1N1) 2009, South Korea. Emerg Infect Dis 2011;17:702-4
   PubMed Web of Science ®Google Scholar
• Hong SD, Park SH, Kang SJ, et al. First fatal oseltamivir-resistant 2009 pandemic influenza A (H1N1) case in an adult in Korea. Chonnam Med J 2011;47:127-9
   PubMedGoogle Scholar
• Hong HL, Kim JH, Yi HJ, Kwon HH. A case of oseltamivir-resistant pandemic influenza (H1N1 2009). Infect Chemother 2010;42:103-6
   Google Scholar
• Kim SA, Kilgore PE, Lee SY, et al. Trends in pneumonia and influenza-associated hospitalizations in South Korea, 2002-2005. J Health Popul Nutr 2011;29:574-82
   PubMed Web of Science ®Google Scholar
• Lee DH, Shin SS, Jun BY, Lee JK. National level response to pandemic (H1N1) 2009. J Prev Med Public Health 2010;43:99-104
   PubMedGoogle Scholar
• Ryoo SM, Kim WY, Sohn CH, et al. Factors promoting the prolonged shedding of the pandemic (H1N1) 2009 influenza virus in patients treated with oseltamivir for 5 days. Influenza Other Respir Viruses 2013;7:833-7
   PubMed Web of Science ®Google Scholar
• Lee JH, Kim M, Lee J, et al. A Case of Acute Pulmonary Thromboembolism Complicated Pandemic Influenza (H1N1 2009). Infect Chemother 2010;42:127-31
   Google Scholar
• Hur JA. A Fatal Case in Pregnant Woman Infected by H1N1 2009 in Korea. Infect Chemother 2011;43:225-8
   Google Scholar
• Park KH, Lee SO, Choi SH, et al. Successful salvage therapy with inhaled zanamivir in a patient with peramivir-resistant pandemic influenza A (H1N1) 2009 virus. Scand J Infect Dis 2011;43:151-5
   PubMed Web of Science ®Google Scholar
• Kim WY, Suh GY, Huh JW, et al. Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation. Antimicrob Agents Chemother 2011;55:5703-9
   PubMed Web of Science ®Google Scholar
• Kohno S, Yen MY, Cheong HJ, et al. Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. Antimicrob Agents Chemother 2011;55:5267-76
   PubMed Web of Science ®Google Scholar
• Park S, Kim JI, Lee I, et al. Combination effects of peramivir and favipiravir against oseltamivir-resistant 2009 pandemic influenza A (H1N1) infection in mice. PLoS One 2014;9:e101325
   PubMed Web of Science ®Google Scholar
• Choi WS, Lee J, Lee HY, et al. Clinical practice guideline for antiviral treatment and chemoprophylaxis of seasonal influenza. Infect Chemother 2012;44:233-49
   Google Scholar
• Choi WS, Baek JH, Seo YB, et al. Severe influenza treatment guideline. Korean J Intern Med 2014;29:132-47
   PubMed Web of Science ®Google Scholar
• Korea Food and Drug Agency. Preliminary analysis of reported cases for Tamiflu side-effects. Pub Health Wkly Rep 2009;50:848-9
   Google Scholar
• Lee JS, Park SH, Moon JW, et al. Modeling for estimating influenza patients from ILI surveillance data in Korea. Osong Public Health Res Perspect 2011;2:89-93
   PubMedGoogle Scholar
• Dutkowski R, Thakrar B, Froehlich E, et al. Safety and pharmacology of oseltamivir in clinical use. Drug Saf 2003;26:787-801
   PubMed Web of Science ®Google Scholar
• Urushihara H, Doi Y, Arai M, et al. Oseltamivir prescription and regulatory actions vis-a-vis abnormal behavior risk in Japan: drug utilization study using a nationwide pharmacy database. PLoS One 2011;6:e28483
   PubMed Web of Science ®Google Scholar
• Greene SK, Li L, Shay DK, et al. Risk of adverse events following oseltamivir treatment in influenza outpatients, Vaccine Safety Datalink Project, 2007-2010. Pharmacoepidemiol Drug Saf 2013;22:335-44
   PubMed Web of Science ®Google Scholar
• Seo ES, Park GH, Kim SW, et al. Oseltamivir efficacy, side effects, and safety in children with influenza. Korean J Pediatr 2010;53:56-66
   Google Scholar